The Association of Globulin Level with Treatment Response and Overall Survival in Patients with Multiple Myeloma
Objectives: An increased globulin level, along with a decreased albumin level, is one of the hallmarks of multiple myeloma (MM). Albumin level has been included in the risk assessment of patients with MM; however, there are insufficient data on the prognostic value of globulin level. The aim of this study was to determine the association of globulin level at diagnosis with the treatment response and overall survival (OS) in patients with MM.
Methods: This study was a retrospective analysis of 30 patients who were diagnosed with MM, followed up, and had their globulin level recorded at the time of diagnosis at the University of Health Sciences Istanbul Training and Research Hospital Department of Hematology between June 2013 and August 2016.
Results: The median age of the patients was 61 years (range: 34-71 years). Eleven patients were female (36.6%) and 19 were male (63.4%). The median globulin level was 4.98 g/dL (range: 2.3-11.6 g/dL), and the cut-off value was 4.9 g/dL, according to the median. The patients were divided into 2 groups: >4.9 g/dL and <4.9 g/dL. Fifteen patients (50%) had a globulin value <4.9 g/dL, whereas 15 (50%) had a globulin value of >4.9 g/dL. The groups were comparable in terms of gender, age, Durie-Salmon stages, kappa/lambda ratios, creatinine value, beta-2 microglobulin level, lactate dehydrogenase level, OS, and treatment response rates (p>0.05). The globulin level was not significantly associated with treatment response or OS (p>0.05).
Conclusion: This study is the first to investigate the role of globulin in patients with MM. An increased globulin level during the course of MM is not a concern for clinicians, as it does not appear to negatively affect treatment response or OS.
1. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv52–61. [CrossRef]
2. Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2016;91:101–19. [CrossRef]
3. Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol 2017;2017:4812637. [CrossRef]
4. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20. [CrossRef]
5. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88:360–76. [CrossRef]
6. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003;29:467–71. [CrossRef]
7. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012;119:2205–8.
8. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269–77. [CrossRef]
9. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–54. [CrossRef]
10. Busher JT. Serum Albumin and Globulin. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths; 1990. Chapter 101.
11. O'Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician 2005;71:105–12.
12. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995;10:128–41. [CrossRef]
13. Chandy KG, Stockley RA, Leonard RC, Crockson RA, Burnett D, MacLennan IC. Relationship between serum viscosity and intravascular IgA polymer concentration in IgA myeloma. Clin Exp Immunol 1981;46:653–61.